As a result (Fig. S3A, B), lower expression of CD31 and VEGF was detected in the combination treatment group, suggesting that PLX3397 was able to reduce the microvessel density and inhibit neoangiogenesis in ovarian cancer tissues after paclitaxel chemotherapy. Here, PECAM1 is linked to ovarian cancer.